Receptos to Present at Leerink Global Healthcare Conference
09 Febbraio 2015 - 2:00PM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that Faheem Hasnain, its
President and Chief Executive Officer, will be presenting at the
Leerink Global Healthcare Conference at the Waldorf Astoria hotel
in New York City. The presentation is scheduled as a fireside chat
on Thursday, February 12 at 1:25 p.m. Eastern Time.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, RPC1063, is a sphingosine
1-phosphate 1 and 5 receptor small molecule modulator in
development for immune indications including RMS and
IBD. Patents supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a (MM) (NASDAQ): 0 articoli recenti
Più Articoli Notizie